MM
NBIX icon

MQS Management’s Neurocrine Biosciences NBIX Stock Holding History

MQS Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$326K Buy
2,471
+429
+21% +$56.9K 0.22% 188
2025
Q4 		$290K Buy
+2,042
New +$296K 0.17% 258
2024
Q4 		– Sell
-1,769
Closed -$204K – 254
2024
Q3 		$204K Sell
1,769
-1,103
-38% -$151K 0.11% 371
2024
Q2 		$395K Sell
2,872
-1,126
-28% -$154K 0.24% 167
2024
Q1 		$551K Buy
+3,998
New +$546K 0.32% 102
2023
Q3 		– Sell
-3,024
Closed -$285K – 557
2023
Q2 		$285K Buy
3,024
+11
+0.4% +$1.07K 0.19% 241
2023
Q1 		$305K Buy
+3,013
New +$314K 0.2% 230

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MQS Management's NBIX Position: Q1 2026 in Review

MQS Management increased its Neurocrine Biosciences (NBIX) stake by 21% in Q1 2026, buying an estimated $56.9K and bringing the position to 2,471 shares worth $326K. The position accounts for 0.22% of the portfolio, ranked #188.

MQS Management first reported a position in NBIX in Q1 2023 and has held it in 7 quarters since. The position peaked at $551K in Q1 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • MQS Management held 2,471 shares of Neurocrine Biosciences worth $326K as of Q1 2026.
  • MQS Management bought 429 Neurocrine Biosciences shares in Q1 2026, an estimated $56.9K.
  • Neurocrine Biosciences made up 0.22% of MQS Management's portfolio in Q1 2026, its #188 holding.
  • MQS Management first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 7 quarters since.
  • MQS Management's Neurocrine Biosciences position peaked at $551K in Q1 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on MQS Management's 13F filing for Q1 2026, filed 23 Apr 2026.